Patent application number | Description | Published |
20090069250 | Inhibitors of Histone Deacetylase - The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and sale dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo. | 03-12-2009 |
20090069391 | Benzothiophene hydroxamic acid derivatives - The present invention relates to a novel class of hydroxamic acid derivatives. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo. | 03-12-2009 |
20090105264 | Substituted Nicotinamide Compounds - The present invention relates to a novel class of substituted nicotinamides. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo. | 04-23-2009 |
20100160327 | Modified Malonate Derivatives - The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the modified malonate derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the modified malonate derivatives in vivo. | 06-24-2010 |
20110082136 | INHIBITORS OF JANUS KINASES - The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer. | 04-07-2011 |
20110112081 | INHIBITORS OF JANUS KINASES - The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2). The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 and TYK2 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer. | 05-12-2011 |
20110130393 | INHIBITORS OF JANUS KINASES - The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2). The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 and TYK2 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer. | 06-02-2011 |
Patent application number | Description | Published |
20110231162 | System and Method for Generating Enhanced Density Distribution in a Three Dimenional Model of a Structure for Use in Skeletal Assessment Using a Limited Number of Two-Dimensional Views - A method of generating a density enhanced model of an object is described. The method includes generating a customized a model of an object using a pre-defined set of models in combination with at least one projection image of the object, where the customized model is formed of a plurality of volume elements including density information. A density map is generated by relating a synthesized projection image of the customized model to an actual projection image of the object. Gains from the density map are back-projected into the customized model to provide a density enhanced customized model of the object. Because the density map is calculated using information from the synthesized projection image in combination with actual projection images of the structure, it has been shown to provide spatial geometry and volumetric density results comparable to those of QCT but with reduced patient exposure, equipment cost and examination time. | 09-22-2011 |
20130308752 | Apparatus and Method for Detecting Lymphedema Using X-Ray Scans - A system for detecting lymphedema comprising a dual energy x-ray absorptiometry system and one or more spacer pads disposed within a field of view of the dual energy x-ray absorptiometry system. The dual energy x-ray absorptiometry system comprising an x-ray source and a patient support platform, wherein the patient support platform is configured to receive a patient in a supine position with the x-ray source disposed above the patient support platform. The one or more spacer pads configured to be positioned between body parts of the patient. | 11-21-2013 |
20140222391 | System and Method for Generating Enhanced Density Distribution in a three Dimensional Model of a Structure for Use in Skeletal Assessment Using a Limited Number of Two Dimensional Views - A method of generating a density enhanced model of an object is described. The method includes generating a customized a model of an object using a pre-defined set of models in combination with at least one projection image of the object, where the customized model is formed of a plurality of volume elements including density information. A density map is generated by relating a synthesized projection image of the customized model to an actual projection image of the object. Gains from the density map are back-projected into the customized model to provide a density enhanced customized model of the object. Because the density map is calculated using information from the synthesized projection image in combination with actual projection images of the structure, it has been shown to provide spatial geometry and volumetric density results comparable to those of QCT but with reduced patient exposure, equipment cost and examination time. | 08-07-2014 |
20150146851 | BONE DENSITOMETER - A method includes moving a radiation source and a radiation detector along a scan path substantially transverse to a longitudinal axis of a patient. A beam of radiation is emitted from the radiation source. The beam of radiation is detected at the radiation detector. The detected beam is processed so as to form a first image of a first area of the patient along the scan path. | 05-28-2015 |
Patent application number | Description | Published |
20120161909 | Multi Integrated Switching Device Structures - A switching device structure having a top layer and a bottom layer, each layer comprising a body of magnetizable material, such as permalloy, disposed within a coil wherein an armature is suspended in a cavity between the top and bottom layers, the armature having ferromagnetic material disposed on a top and bottom surface thereof. Each body of magnetizable material may be pulsed by its respective coil to switch it from a magnetic state to a non-magnetic state and then subsequently pulsed by the coil to switch it from the non-magnetic state to a magnetic state. | 06-28-2012 |
20130082807 | Multi Integrated Switching Device Structures - A permanent magnet is pivotally mounted in a top spacer layer of a switching device and rests on a flex arm created in an underlying flex circuit layer. The underside of the flex arm rests on a thin bar formed in a lower spacer layer beneath which lies a base layer including an electromagnet. Activation of the electromagnet causes rotation of the flex arm to thereby close and open electrical contacts formed respectively on the underside of the flex arm and on the top surface of the base layer. | 04-04-2013 |
20150155123 | Multi Integrated Switching Device Structures - A switching device structure having a top layer and a bottom layer, each layer comprising a body of magnetizable material, such as permalloy, disposed within a coil wherein an armature is suspended in a cavity between the top and bottom layers, the armature having ferromagnetic material disposed on a top and bottom surface thereof. Each body of magnetizable material may be pulsed by its respective coil to switch it from a magnetic state to a non-magnetic state and then subsequently pulsed by the coil to switch it from the non-magnetic state to a magnetic state. | 06-04-2015 |
Patent application number | Description | Published |
20120264735 | TYROSINE KINASE INHIBITORS - The present invention relates to pyridazin-4(1H)-one derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals. | 10-18-2012 |
20130116231 | TYROSINE KINASE INHIBITORS - The present invention relates to 1,4-dihydropyridazinone derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals. | 05-09-2013 |
20130158041 | Tyrosine Kinase Inhibitors - The present invention relates to pyridazinthione derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals. | 06-20-2013 |